顾问公司贝恩咨询Bain合伙人安德鲁·帕斯特纳克(Andrew Pasternak)表示，与生产普通非专利药品相比，生产仿生物药品涉及的技术更加复杂。
The science involved in making biosimilars is much more complicated than that in making ordinary generics, says Andrew Pasternak of Bain &Company, a consultancy.
顾问公司贝恩咨询Bain合伙人安德鲁·帕斯特纳克(Andrew Pasternak)表示，与生产普通非专利药品相比，生产仿生物药品涉及的技术更加复杂。
The science involved in making biosimilars is much more complicated than that in making ordinary generics, says Andrew Pasternak of Bain &Company, a consultancy.
应用推荐